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Background: The liver has a large regenerative capacity. Hepatocytes can replicate and regenerate a diseased liver.
However, as is the case in severe liver diseases, this replication may become insufficient or exhausted and hepatic
progenitor cells (HPCs) can be activated in an attempt to restore liver function. Due to their bi-potent differentiation
capacity, these HPCs have great potential for regenerative approaches yet over-activation does pose potential
health risks. Therefore the mechanisms leading to activation must be elucidated prior to safe implementation in the
veterinary clinic. Wnt/β-catenin and Notch signalling have been implicated in the activation of HPCs in mouse
models and in humans. Here we assessed the involvement in canine HPC activation. Gene-expression profiles were
derived from laser microdissected HPC niches from lobular dissecting hepatitis (LDH) and normal liver tissue, with a
focus on Wnt/β-catenin and Notch signalling. Immunohistochemical and immunofluorescent studies were
combined to assess the role of the pathways in HPCs during LDH.
Results: Gene-expression confirmed higher expression of Wnt/β-catenin and Notch pathway components and
target genes in activated HPC niches in diseased liver compared to quiescent HPC niches from normal liver.
Immunofluorescence confirmed the activation of these pathways in the HPCs during disease.
Immunohistochemistry showed proliferating HPCs during LDH, and double immunofluorescence showed
downregulation of Wnt/β-catenin and Notch in differentiating HPCs. Vimentin, a mesenchymal marker, was
expressed on a subset of undifferentiated HPCs.
Conclusions: Together these studies clearly revealed that both Wnt/β-catenin and Notch signalling pathways are
enhanced in undifferentiated, proliferating and potentially migrating HPCs during severe progressive canine liver
disease (LDH).
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Liver diseases occur frequently in the canine pet popula-
tion. Around 12% of the dogs in first opinion practices
have liver disease [1,2] and account for 1-2% of a univer-
sity veterinary clinical population [3]. It is conceivable that
these numbers, based on the Cambridge region (UK) and
the Utrecht University Clinics (the Netherlands), respect-
ively, are exemplary for the West-European dog pet popu-
lation. One third of chronic hepatitis cases are caused by
copper accumulation. In addition, microorganisms, toxins
and drugs have been reported to cause hepatitis in dogs.* Correspondence: B.A.Schotanus@uu.nl
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unless otherwise stated.In more than 60% of cases, however, hepatitis remains
idiopathic [3,4]. The recently discovered canine hepaci-
virus is unlikely to cause canine hepatitis [5-7].
Irrespective of the cause of hepatocyte damage, the
liver can recover from such insults due to replication of
fully differentiated hepatocytes [8]. In case this replica-
tion is exhausted or otherwise hampered, hepatic pro-
genitor cells (HPCs) are reported to have the potential
to take over regeneration. These stem cells are believed
to be bi-potential and to have the capacity to differenti-
ate into either hepatocytes or cholangiocytes, depending
on cellular demand [9]. HPCs are located in the ter-
minal branches of the biliary tree, called the Canal of
Hering [10]. Several publications describe the cellular
and molecular constituents of the canine or feline HPCtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the liver, but it has a biological function as it provides
the cell- and matrix derived signals to instruct the HPC’s
cellular fate.
In order to safely use HPCs for liver regeneration in
a clinical setting where hepatocyte replication is insuf-
ficient, detailed knowledge of crucial signalling cas-
cades for HPC activation is essential. Two signalling
pathways, Wnt/β-catenin and Notch, are involved in
proliferation and differentiation of progenitor cells
including HPCs in other mammals [16-20]. This prompted
the present focus on these two transmembrane signalling
pathways in the activation of HPCs in canine liver diseases.
Since lobular dissecting hepatitis (LDH) was previously
observed to contain the highest number of activated
HPCs, the activated HPC niche from LDH was micro-
dissected and molecular analyses were performed in
comparison with quiescent HPC niches harboured adja-
cent to portal areas of normal canine liver [13].
These data show that both Wnt/β-catenin and Notch
signalling are enhanced in activated HPC niches in dogsFigure 1 Gene expression of Wnt and Notch signalling components is
(6 μm) of normal liver and lobular dissecting hepatitis immunostained for Ker
the quiescent HPC niche in the periportal area of normal tissue and the activa
areas were specifically selected by means of laser microdissection for RNA
components of Wnt (B), and Notch (C) signalling pathways show upregu
1; TCF3, transcription factor 3; AXIN2, axis inhibitor 2; JAG, jagged; HEY1, h
N/D, not detectable.with LDH. The previous descriptions of the cellular
constituents of the canine HPC niche and the current
investigation on specific signalling cascades clearly show
the similarities with other mammals, including human
[12,13]. It is therefore conceivable that results of clinical
approaches in human medicine will be applicable and
beneficial in veterinary health care.
Results
Gene-expression profiling of laser microdissected HPC
niches indicate activation of Wnt and Notch pathways
Representative pictures of laser microdissected HPC
niches in normal liver and lobular dissecting hepatitis
(LDH) stained with Keratin(K)7 (marker of HPCs) are
depicted in Figure 1A. Expression levels of the Wnt re-
ceptor FZD1 and the Wnt-induced transcription factor
TCF3 were significantly higher in LDH cases compared to
normal controls, as measured in LMD samples (Figure 1B).
Of the various Notch-receptor proteins, only NOTCH1
and NOTCH3 expression levels were significantly higher
in diseased material (Figure 1C). In line is the observationenhanced in HPC niches during disease. Examples of cryosections
atin 7 (A), a marker of HPCs and cholangiocytes. The red lines indicate
ted HPC niche throughout the parenchyma of diseased tissue (A). These
isolation and gene expression analysis. Relative gene-expression for
lation of these pathways in HPC niches during disease. FZD1, Frizzled
airy/enhancer of split-related with YRPW motif; N.S., not significant;
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not (Figure 1C). Based on these expression levels of
ligand and receptors, it was anticipated that an activated
Wnt/β-catenin and Notch signalling cascade would be
present in activated HPC niches (Figure 1B,C). Import-
antly, the expression levels of classical target genes
for Wnt/β-catenin, AXIN2, and Notch signalling, HEY1,
were indeed elevated in LDH, confirming active down-
stream signalling (Figure 1B,C).
Immunofluorescence confirm activated Wnt/β-catenin and
Notch signalling in HPC during disease
To specify the cellular origin of the upregulated gene
expression levels, double immunofluorescence for β-catenin/
K7 (Figure 2A) and Notch1/Notch Intra Cellular Domain
(NICD)/K7 was performed (Figure 2B). This revealed
that β-catenin and Notch1/NICD were strongly expressed
in the cytoplasm and/or nucleus of the cells of the duct-
ular reaction in LDH. Expression of β-catenin in hepato-
cytes and cholangiocytes was membranous, indicative
for a low activation status of the Wnt/β-catenin signal-
ling cascade. Similarly, Notch1/NICD was expressed in
canalicular- and less pronounced in basolateral mem-
branes in hepatocytes in normal tissues.Figure 2 Wnt and Notch signalling are active in HPCs during disease.
(15 μm) against β-catenin (green) and Keratin(K)7 (red), with ToPro3 (blue)
indicates 100 μm). In normal tissue, β-catenin is present in a membranous sta
was seen. In LDH, β-catenin is clearly increased and overlay shows cytoplasmi
blue). Example of immunofluorescent double staining on cryosections (15 μm
(red), with ToPro3 (blue) nuclear counterstaining in normal and diseased (LDH
staining pattern on hepatocytes and bile duct cells was found, no nuclear staWnt/β-catenin and Notch signalling coincide with HPC
proliferation and mesenchymal characteristics but are lost
with differentiation
To investigate the functional involvement of Wnt and
Notch in HPC activation, immunohistochemical and im-
munofluorescent stainings were performed (Figure 3).
With Ki67 staining the proliferative activity in the tissues
was assessed. In LDH, very few hepatocytes were found to
be positive for Ki67, while a substantial number of Ki67
positive cells were found in the DR (Figure 3A). To
evaluate the potential of HPCs to obtain mesenchymal
characteristics, immunohistochemical staining for vimen-
tin and double immunofluorescent staining for vimentin
and PanCK was performed (Figure 3B,C). This revealed
strong (co-)staining of vimentin in ductular structures,
clearly showing expression of a mesenchymal marker
on HPCs. To investigate the role of Wnt and Notch in
HPC differentiation during liver disease, the mature hep-
atocyte marker HepPar1 in combination with β-catenin or
Notch1/NICD in a double immunofluorescent staining
was used. A clear polarisation of the ductular reaction was
observed in such a way that the non-differentiated cells
exhibited strong cytoplasmic and sometimes nuclear stain-
ing for both β-catenin and Notch1/NICD. This stainingExample of immunofluorescent double staining on cryosections
nuclear counterstaining in normal and LDH liver tissue (A, size bar
ining pattern on hepatocytes and bile duct cells. No nuclear β-catenin
c and nuclear presence of β-catenin in K7 positive cells (yellow and bright
) against Notch/Notch Intra Cellular Domain (Notch/NICD; green) and K7
) liver tissue (B, size bar indicates 100 μm). In normal tissue, a canalicular
ining was present.
Figure 3 Proliferation and mesenchymal characteristics on HPCs and relation of differentiation with β-catenin and Notch1/NICD
signalling. Immunohistochemical staining for Ki67 shows positive cells in the ductular reaction during LDH (A). Immunohistochemical staining
for vimentin suggests positive ductular reactions (B) and an example of vimentin and PanCK double staining (C) shows clear co-localisation on
HPCs in LDH. Double immunofluorescence against HepPar1 and β-catenin (D) or Notch1/Notch intracellular domain (Notch1/NICD; (E) in LDH
shows polarisation of the ductular reaction: clear cytoplasmic staining of β-catenin or Notch/NICD is present in non-differentiated cells of the
ductular reaction, and only membranous staining is present in differentiating and fully differentiated, HepPar1 positive, hepatocytes. Size bars
indicate 50 μm.
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entiated hepatocytes during continuation of the ductular
reaction (Figure 3D,E). This is in line with the cytoplasmic
and nuclear staining of β-catenin and Notch1/NICD in
the K7-positive undifferentiated HPCs in Figure 2. In all
staining procedures, negative controls remained negative,
indicating the specificity of the antibodies used.
Discussion
In the present study the involvement of the Wnt/β-
catenin and Notch pathways was investigated in canine
hepatic progenitor cell activation in LDH, a highly fibrotic
and progressive liver disease. The combination of laser-
microdissection, gene expression studies (Q-PCR) and
immunofluorescence showed the enhanced signalling of
the Wnt/β-catenin and Notch pathways in activated
HPC niches compared to quiescent HPCs in normalliver. This extends the findings in mouse and human
liver cancer and normal liver regeneration [19,21-27].
The fact that this apparent activation was insufficient to
restore the liver, dogs presenting with LDH die within a
year after diagnosis [4], suggests that therapeutic oppor-
tunities are present here. The reason why HPCs fail
to regenerate the liver seems to vary with the type of
disease and may be due to insufficient proliferation,
migration or differentiation [28]. New therapeutic strat-
egies could address the pathways involved in these
phases of activation.
The effect of Wnt/β-catenin was previously specified
as (induction of) proliferation in rodent models of HPC
activation [16,24,29,30]. Similarly, a regulatory role for
Notch in HPC proliferation is described [31,32]. In LDH,
the concurrent presence of active Wnt and Notch signal-
ling and actively proliferating, Ki67 positive cells in the
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ways in proliferation of canine HPCs during disease as
well. Another functional implication of Wnt and Notch
signalling may relate to the acquisition of mesenchymal
characteristics by HPCs. The presence of mesenchymal
characteristics can relate to migratory potential, which
is not equivalent to full epithelial-mesenchymal tran-
sition (EMT), a disputed phenomenon in adult liver
[33-35]. From a regenerative point of view, migration is
necessary for HPCs to move toward the site of disease
activity, and is likely to occur in concert with prolifera-
tion [36,37]. Wnt and Notch pathways have been impli-
cated in EMT and migratory potential of cells in different
types of tissues and cancer development [38,39]. In canine
LDH vimentin positive HPCs also exhibit Wnt and Notch
signalling, potentially indicating a causative relation in
canine HPCs. It will be of interest to further function-
ally investigate this newly suggested role of Wnt or
Notch in migration of HPCs during disease, as it may pro-
vide interesting potential for therapeutic intervention.
Besides the described role in proliferation and migra-
tion, both pathways can be involved in HPC differenti-
ation. The influence of Wnt on cell fate determination
is time and place dependent. During early embryonic
development and in pluripotent embryonic stem cells
in vitro Wnt activation leads to hepatic specification
[40,41]. Later in foetal liver development and in vitro in
more committed multipotent cells, active Wnt inhibits
(further) hepatocyte differentiation but rather guides
cells to the biliary phenotype [42,43]. Regarding the
HPC as a committed progenitor cell, Wnt activation in
LDH might stimulate bile duct differentiation and in-
hibit hepatocyte differentiation. An interesting finding
in this study is that small hepatocytes lying in conti-
nuation with ductular cells, and possibly representing
intermediate hepatocytes [44], display a membranous
β-catenin staining pattern (Figure 3) similar to that of
hepatocytes in normal tissue. This supports the theory
that the Wnt/β-catenin pathway is no longer active
during hepatocytic differentiation of ductular cells and is
different from previous mouse data [21]. Unfortunately,
the lack of specific markers for intermediate hepatocytes
limits their description to size and localization only
[11,45]. The importance of Notch in liver development
and hepatocyte differentiation is apparent in the muta-
tion in the Notch ligand Jag1, which is associated with
Alagille syndrome, presenting with aberrant bile duct
development [25,46-51]. More recently a distinctive role
for the different Notch receptors has been explored,
suggesting that Jag1-mediated Notch1 and Notch3 acti-
vation stimulates differentiation of hepatoblasts towards
the biliary phenotype and inhibits hepatocytic differenti-
ation. Vice-versa, Notch1 and Notch3 expression would
be lost when (liver progenitor) cells differentiated towardshepatocytes [52,53]. Converting these findings to the
described results, it might be postulated that during
LDH, where NOTCH1 and NOTCH3 expression is in-
creased, HPC differentiation towards hepatocytes is inhib-
ited, while bile duct differentiation may be enhanced. This
is corroborated by the immunofluorescence stainings,
where Notch1/NICD is lost with differentiation.
The activated states of the Wnt and Notch pathway in
the diseased tissue were found at the same histological
location, suggesting that Wnt and Notch act simultan-
eously. In view of this, the Wnt and Notch pathways
may be intertwined in the activation of HPCs during
liver disease, as occurs for example when cell-fate deci-
sions are made during development [54]. Whether and
how Wnt and Notch interact during HPC activation and
in what manner this can be used for therapeutic benefit
needs to be further investigated in molecular in vitro
studies.Conclusions
The combined Q-PCR and immunofluorescence results
extend existing literature on other species and indicate a
critical role for Wnt and Notch in proliferation, differen-
tiation and/or migration of canine HPCs during rapidly
progressing fibrotic liver disease with hampered hepato-
cytic proliferation. The descriptive data presented here
suggest a role in HPC activation; in vitro experiments
with canine hepatic progenitor cells, at present not avail-
able, could shed light on these questions separately.
These data from a non-experimental liver disease in
client-owned pets confirm the previous separate reports
on Wnt and Notch signalling in rat and mouse injury
models of liver disease [16,23,24,29,30,50] and human
data [19]. In the future, the implementation of pre-
clinical experiments with Notch or Wnt inhibitors in
order to enhance liver regeneration in patients could be
mutually beneficial for dog and man.Methods
Liver samples
Liver samples were obtained from privately owned
dogs with LDH (n = 4; age range 1.5-2.5 years), a rap-
idly progressing disease characterized by diffuse in-
flammation, peri-cellular fibrosis and massive HPC
activation [12,13]. Informed consent was obtained as
required under Dutch legislation. Liver pathology of
the dogs was confirmed histologically by one board-
certified veterinary pathologist according to the World
Small Animal Veterinary Association (WSAVA)-standards
[55]. Normal livers (n = 4; age range 1-3 years) were
obtained from surplus animals of a non-liver related re-
search project at the University Medical Centre Utrecht
(University 3R policy).
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Cryosections (10 μm) were cut using RNAse free blades
on a cryostat at -20°C (Leica CM3050 cryostat, Leica
Microsystems GmbH, Wetzlar, Germany), mounted on a
pre-cooled (4°C) RNAse-free poly-ethylene naphthalene
(PEN) membrane slide (P.A.L.M. MicroLaser Technologies
AG, Burnried, Germany), immediately placed on dry ice
and stored at -70°C for a maximum of one week until use.
Rapid immunohistochemistry before laser microdissection
(LMD) was performed with buffers and solutions prepared
with DEPC-treated water (Ambion, Austin, TX). All glass-
ware was treated with RNase Zap (Ambion) and washed
with DEPC-treated water prior to use. To protect RNA
from degradation during incubations at room temperature
(RT), antibody and DAB solutions were prepared with
0.4 U/μl SUPERase RNase Inhibitor (Ambion). Frozen
sections were taken from -70°C storage, immediately
fixed in ice-cold acetone (-20°C) for 5 minutes and
washed briefly (3-5 seconds) in phosphate-buffered sa-
line (PBS). Sections were incubated with K7 antibody
(1:20; Dako, Glostrup, Denmark) in PBS for 7 minutes
at RT, briefly washed in PBS and subsequently incubated
in EnVision goat anti-mouse peroxidase-conjugated
antibody (Dako) for 7 minutes at RT. Staining was visua-
lised using the chromogen diaminobenzidine (DAB; Dako)
for 3 minutes at RT. Finally, sections were dehydrated
in an EtOH series (75-95-100%, 15 seconds each). The
LMD procedure was performed within a maximum of
20 minutes upon staining with a Nikon eclipse TE300
inverted microscope (Nikon Inc. Instrument Group,
Melville, NY) connected to a Sony 3-CCD Microscope
ColorColour Video Camera (Sony Electronics Inc., Tokyo,
Japan) using MMI CellTools software (MMI Molecular
Machines & Industries AG, Glattbrugg, Switzerland).
Tubes with an adhesive lid (MMI) were used to remove
laser dissected cells from the whole liver tissue slide.
After the LMD procedure, collected cells were retrieved
with 50 μl Extraction Buffer (PicoPure RNA isolation
kit, Molecular Devices, MDS Analytical Technologies,
Sunnyvale, CA) and a short centrifugal step for further
molecular processing. The cell-suspension was then in-
cubated at 42°C for 30 min, centrifuged for 2 minutes at
800 × g, snap frozen in liquid nitrogen and stored
at -70°C until further use. From each sample, a total of
2-3.5 × 106 μm2 tissue was laser-dissected using four tis-
sue sections per normal sample and two tissue sections
per diseased sample.
RNA isolation and amplification
Total RNA was extracted from the LMD samples using the
PicoPure RNA isolation kit (MDS Analytical Technologies)
according to the manufacturer’s instructions and an on
column DNAse treatment (0.1 U/μl) to remove allDNA contaminations (Qiagen, Benelux BV, Venlo, The
Netherlands). RNA quality after LMD was determined
using a RNA 6000 Pico-LabChip with an Agilent BioAna-
lyzer 2100 (Agilent, Palo Alto, CA). Amplification of the
RNA was performed with the WT-Ovation™ Pico RNA
Amplification System according to the manufacturer’s
instructions (NuGEN Technologies Inc., Bemmel, The
Netherlands). Making use of a DNA/RNA chimeric pri-
mer, cDNA was prepared from total RNA and amplified
by linear isothermal DNA amplification. The product con-
sists of single-strand DNA (ssDNA). The amplified product
was purified with DNA Clean & Concentrator-25 from
Zymo research according to the manufacturers instruction
(Baseclear Lab Products, Leiden, The Netherlands),
replacing Wash Buffer by fresh 80% ethanol.
Q-PCR analysis
For gene expression analysis, a SYBR Green based quan-
titative RT-PCR (Q-PCR) was performed on a Bio-Rad
My-IQ detection system as described previously [56] for
up to 45 cycles. Gene expression of described markers of
HPCs and hepatocytes and of components of the Wnt/
β-catenin and Notch signalling pathways was measured.
Details of the primers and PCR conditions are listed in
Table 1. Sequencing reactions confirmed amplification of
the specific primer products in the Q-PCR reaction.
Normalisation was secured due to the use of at least
three independent reference genes: B2MG, HPRT, RPS5,
and RPS19.
Statistical analysis
Relative gene expression of each gene-product (delta-Cq
method) was used as the basis for all comparisons. The
non-parametric Mann-Whitney U test was performed
to assess statistical differences between normal and
diseased tissue using SPSS software (SPSS Benelux,
Gorinchem, the Netherlands). Gene expressions that
were not detectable were arbitrarily set to Cq 45 for
statistical analysis. p-Values < 0.05 were considered
statistically significant.
Immunohistochemistry/-fluorescence
Antibody details for immunohistochemistry/-fluorescence
can be found in Table 2.
Whole liver cryosections (6 μm) were immunohisto-
chemically stained for Ki67, a marker of active cell pro-
liferation. Slides were air dried for 30 minutes at RT,
fixed in ice-cold aceton:methanol 1:1 and washed in
phosphate buffered saline with 0.1% Tween 20 (PBS/T,
pH 7.4). Endogenous peroxidase activity was blocked for
30 minutes at RT in 0.3% H2O2 in PBS/T and back-
ground staining was blocked with 10% normal goat
serum in PBS/T for 30 minutes at RT. Primary antibody
was diluted in blocking serum and incubated for 60
Table 1 Primers and PCR conditions
Gene Direction Sequence (5’- 3’) Tm (°C) Product size (bp) Genbank accession number
B2MGa Forward TCCTCATCCTCCTCGCT 60.3 85 XM_535458
Reverse TTCTCTGCTGGGTGTCG
HPRTa Forward AGCTTGCTGGTGAAAAGGAC 58 114 NM_001003357
Reverse TTATAGTCAAGGGCATATCC
RPS5a Forward TCACTGGTGAGAACCCCCT 62.5 141 XM_533568
Reverse CCTGATTCACACGGCGTAG
RPS19a Forward CCTTCCTCAAAAAGTCTGGG 61 95 XM_533657
Reverse GTTCTCATCGTAGGGAGCAAG
FZD1 Forward GGCGCAGGGCACCAAGAAG 58.8 97 XM_539411
Reverse GAGCGACAGAATCACCCACCAGA
TCF3 Forward GGTGAATGAGCGGGTCCTGAACA 58.8 128 XM_849145
Reverse TGAGCTGGCTGGCACGGTAGTC
AXIN2 Forward CACCCGCTCTACAACAAGGT 60 128 XM_548025
Reverse AGGTGGAGATGAAGCACAGC
NOTCH1 Forward TACCGGCCAGAACTGTGAGGAGAA 56 108 XM_537795
Reverse GGAGGGCAGCGGCAGTTGTAAGTA
NOTCH2 Forward AGCACGCATCCTGGCATACCTC 58.3 106 XM_853135
Reverse TGGGGATTAGCTGGAAAGTCACAA
NOTCH3 Forward TCTGCCAGAGTTCCGTGGTG 66.8 117 XM_847948
Reverse ATGGGGTACAAGGGCTGCTG
NOTCH4 Forward GGAAGGGAGCCAGGGACCAACACA 68 96 NM_004557
Reverse TCAGGGCCACAGCGGGACAAATC
JAG1 Forward GGGCAACACCTTCAATCTCAAG 58.5 122 XM_853730
Reverse CATTACTGGAATCCCACGCTTC
JAG2 Forward GGGTACGTGCGTGGGC 64 XM_548004
Reverse CACCGTTGTAGCAAGGCAG
HEY1 Forward CCAGGAAAAGACGAAGAGGC 62.5 226 NM_001002953
Reverse CTCCGATAGTCCATAGCAAGGG
Table legend text. aReference genes.
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Staining was visualised using diaminobenzidine (DAB;
Dako) and counter stained with haematoxylin quickstain
(Vector Laboratories) for 5 minutes. Finally, slides were









Mu: Mouse; Rb: Rabbit; Mo: monoclonal; Po: polyclonal. TE: Tris/EDTA.duodenum served as the positive control (data not shown).
Immunohistochemistry for vimentin was performed
on 4 μm thick, paraffin embedded sections essentially
as described previously [13]. Immunohistochemical
pictures were obtained using an Olympus BX41TFCompany Antigen retrieval Dilution
Abcam TE pH9 1:2,000
Dako TE pH9 1:50
Dako 1:50
LabVision 1:50
Dako TE pH9 1:400
Santa Cruz TE pH9 1:100
Abcam TE pH9 1:200
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an Olympus U-CMAD3 camera and CellˆB software
(AnalySIS, Olympus).
Immunofluorescent stainings were performed with
parallel antibody incubations. The slides were incubated
with mixed primary antibodies over night at 4°C and
with mixed secondary antibodies at RT for 60 minutes.
Rinsing steps were performed using TBS with 0.1%
Tween 20 and slides were covered with Aquamount
(Vector Laboratories). Immunofluorescent double stainings
for K7/β-catenin and K7/Notch1-NICD were performed on
15 μm ice-cold acetone fixed (normal and LDH) liver-
cryosections. Immunofluorescent double stainings against
PanCK/Vimentin, HepPar/β-catenin and HepPar/Notch1-
NICD were performed on 4 μm paraffin embedded canine
LDH liver sections essentially as described previously
[13]. For Notch1-NICD, incubation in 0.5% Triton for
20 minutes at RT was included for permeabilisation.
The nucleus was stained with ToPro3 or DAPI. Slides
were analysed using a Leica TCS SPE-II Confocal micro-
scope and Leica software. In all procedures, negative
controls were included constituting of a bilateral isotype
control.
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